Glucocorticoid-induced gastrointestinal complications and prophylaxis

Abstract

CLC Number:

MENG Long, CHEN Yong-fei, ZHANG Jin-ping, FANG Yun. Glucocorticoid-induced gastrointestinal complications and prophylaxis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 596-600.

References

[1] 李丹丹,陆进明. 糖皮质激素在类风湿关节炎中的应用进展[J] , 中国临床药理学与治疗学, 2012, 17(1): 116-120.
[2] Gallant C, Kenny P. Oral Glucocorticoids and Their Complications: A Review[J]. J Am Acad Dermatol,1986, 14 (2): 161-177.
[3] 叶洁桐, 陈光兰, 徐芳, 等. 风湿病患者糖皮质激素相关性溃疡35例临床分析[J].浙江中西医结合杂志, 2011, 21(11): 812-813.
[4] Trikudanathan S, McMahon GT. Optimum Management of Glucocorticoid-Treated Patients[J]. Nat Clin Pract Endocrinol Metab, 2008, 4 (5): 262-271.
[5] Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids[J]. Pharmacol Ther, 2002, 96 (1): 23-43.
[6] Richardson CT. Pathogenetic factors in peptic ulcer disease[J] , Am J Med, 1985, 79 (2C): 1-7.
[7] Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer[J]. N Engl J Med, 1976, 294 (9): 473-479.
[8] Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease[J] , N Engl J Med, 1983, 309 (1): 21-24.
[9] Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy[J]. J Intern Med, 1994, 236 (6): 619-632.
[10] Conn HO, Poynard T. Adrenocorticosteroid administration and peptic ulcer: a critical analysis[J]. J Chronic Dis, 1985, 38 (6): 457-468.
[11] van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial[J]. Ann Intern Med, 2002, 136 (1): 1-12.
[12] Munson JC, Kreider M, Chen Z, et al. Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis[J]. Pharmacoepidemiol Drug Saf, 2010, 19 (7): 756-762.
[13] Hernandez-Diaz S, A Rodriguez L. Steroids and risk of upper gastrointestinal complications[J].Am J Epidemiol, 2001, 153 (11): 1089-1093.
[14] Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs[J]. Ann Intern Med, 1991, 114 (9): 735-740.
[15] Carson JL, Strom BL, Schinnar R, et al. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids[J]. Am J Med, 1991, 91 (3): 223-228.
[16] Vella V. Drug-induced peptic ulcer disease[J]. Journal of The Malta College Of Pharmacy Practice, 2005, 10: 15-19.
[17] Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. a meta-analysis[J]. Ann Intern Med, 1991, 115 (10): 787-796.
[18] Bijlsma JW, Boers M, Saag KG, et al. Glucocorticoids in the treatment of early and late ra[J]. Ann Rheum Dis, 2003, 62 (11): 1033-1037.
[19] Garcia EB, Michaud K, Wolfe F. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists[J]. J Rheumatol, 2006, 33 (4): 779-784.
[20] Seager JM, Hawkey CJ. Abc of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs[J]. BMJ, 2001, 323 (7323): 1236-1239.
[21] Olsen M, Christensen S, Riis A, et al. Preadmission Use of Systemic Glucocorticoids and 30-Day Mortality Following Bleeding Peptic Ulcer: A Population-Based Cohort Study[J]. Am J Ther, 2010, 17 (1): 23-29.
[22] Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use[J]. Arthritis Rheum, 2006, 55 (3): 420-426.
[23] Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects[J]. Int J Dermatol, 2010, 49 (3): 239-248.
[24] McDonough AK, Curtis JR, Saag KG. The Epidemiology of Glucocorticoid-Associated Adverse Events[J]. Curr Opin Rheumatol, 2008, 20 (2): 131-137.
[25] Longui CA. Glucocorticoid therapy: minimizing side effects[J]. J Pediatr (Rio J), 2007, 83 (5 Suppl): S163-177.
[26] Yachimski PS, Farrell EA, Hunt DP, et al. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice[J]. Arch Intern Med, 2010, 170 (9): 779-783.
[27] Stanbury RM, Graham EM. Systemic corticosteroid therapy--side effects and their management[J]. Br J Ophthalmol, 1998, 82 (6): 704-708.
[28] McDougall D, Bhibhatbhan A, Toth C. Adverse effects of corticosteroid therapy in neuromuscular diseased patients are common and receive insufficient prophylaxis[J]. Acta Neurol Scand, 2009, 120 (5): 364-367.
[29] McDougall D, Bhibhatbhan A, Toth C. Adverse effects of corticosteroid therapy in neuromuscular diseased patients are common and receive insufficient prophylaxis[J]. Acta Neurol Scand, 2009, 120 (5): 364-367.